Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
INBRX-109 + pemetrexed
- Development stage
- Unknown
- Lead developer
- Inhibrx
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
INBRX-109 + pemetrexed is a combination therapy consisting of INBRX-109 (ozekibart), a recombinant humanized tetravalent monoclonal antibody that acts as an agonist of death receptor 5 (DR5), and pemetrexed, an antimetabolite chemotherapy agent. INBRX-109 induces apoptosis in tumor cells through DR5 activation, with favorable safety and anti-tumor activity observed in clinical studies[4][2][5]. Pemetrexed inhibits folate-dependent enzymes essential for DNA synthesis and cell replication. This combination is under investigation primarily for malignant pleural mesothelioma and other metastatic or unresectable solid tumors as part of expansion cohorts in phase 1 studies[1]. The combination aims to enhance anti-tumor efficacy by leveraging synergistic apoptotic and cytotoxic effects.
- Brand names
- ozekibart
- Other names
- INBRX-109 + pemetrexed
02
Targets
TNFRSF10B (DR5)ATIC (Aminoimidazole carboxamide ribonucleotide transformylase)DHFR (Dihydrofolate reductase)GART (GAR transformylase)TS (Thymidylate synthase)
Beyond the preview
Go deeper on INBRX-109 + pemetrexed.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on INBRX-109 + pemetrexed.